The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

Abstract High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, h...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Yongfeng Wu, Jinming Xu, Jiawei Xu, Yiqing Wang, Luming Wang, Wang Lv, Jian Hu
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2020-04-01
Serie:	Biomarker Research
Soggetti:	Tumor mutation burden TMB Age Immune checkpoint inhibitor ICI NSCLC
Accesso online:	http://link.springer.com/article/10.1186/s40364-020-00188-2
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!